Novo Nordisk A/S (NVO) 43.76 $NVO
Baxter Announces Positive Data for BAX 855; Competition Rife - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 12:40PM CST
Baxter International Inc. (BAX) recently disclosed additional efficacy and safety data from its Phase III pivotal study evaluating BAX 855 which is used to treat patients with hemophilia A.
NVO: 43.76 (+0.61), BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)
Research and Markets: Global Insulin Delivery Devices Market 2014-2018: Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co Account for 90% of Global Share
Business Wire - Wed Feb 11, 11:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/jgc6fb/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering.
NVO: 43.76 (+0.61), LLY: 70.56 (+0.03)
Global Insulin Delivery Devices Market 2014-2018: Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co Account for 90% of Global Share
M2 - Wed Feb 11, 9:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/hjxrhm/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. This study thus leads to the proposition that innovation has huge scope in the field of insulin delivery and its analysts have elaborate information on some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co. These players together account for more than 90% of the global market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/hj...al_insulin
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), PODD: 32.00 (-0.07), NVO: 43.76 (+0.61), MDT: 75.26 (+0.33), LLY: 70.56 (+0.03)
Don't Worry About Orexigen's Obesity Drug EU Approval
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 8:34AM CST
Someone in Europe isn't too happy that Orexigen 's obesity drug, Mysimba, got a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP. The drug, which goes by the name Contrave in the U.S., will be reviewed in a...
JNJ: 99.62 (+1.18), OREX: 5.55 (+0.10), ECYT: 5.26 (-0.02), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
International GPCR Consortium Announces Addition of New Members Novo Nordisk and Merck & Co., Inc
PR Newswire - Tue Feb 10, 7:00AM CST
The GPCR Consortium, an international nonprofit collaboration that comprises leading academic research institutes in the United States and China and major pharmaceutical companies from around the world, today announced two new members. Novo Nordisk and Merck & Co., Inc, known as MSD outside the United States and Canada, have joined Amgen, Sanofi and Ono in the GPCR Consortium, bringing the current pharma membership to five. The research funded by the GPCR Consortium is currently conducted at the Bridge Institute at the University of Southern California, Shanghai Institute of Materia Medica, and the iHuman Institute at ShanghaiTech University.
NVO: 43.76 (+0.61), AMGN: 153.48 (+0.30)
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 6 February 2015
GlobeNewswire - Mon Feb 09, 8:05AM CST
In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.
NVO: 43.76 (+0.61)
Forget About Ebola Stocks and Invest in This Instead
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:59AM CST
There's no question that Ebola is a frightening disease that requires significant attention, but investors should be careful about how much of their portfolio they invest in companies pursuing Ebola therapies. After all, Ebola is an uncommon disease,...
OREX: 5.55 (+0.10), VRTX: 113.66 (+4.03), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), QSII: 17.04 (+0.38), MDRX: 11.80 (+0.04), ARNA: 4.55 (+0.02)
Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme
GlobeNewswire - Mon Feb 09, 7:36AM CST
On 30 January 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2015.
NVO: 43.76 (+0.61)
Miraculins Moves Closer to Commercialization
ACCESSWIRE - Mon Feb 09, 7:01AM CST
WHITEFISH, MT / ACCESSWIRE / February 9, 2015 / Diabetes is the seventh leading cause of death in the United States with over a million new cases each year, according to the American Diabetes Association, costing the healthcare system $176 billion in direct costs and the economy $76 billion in lost productivity in 2012.
PODD: 32.00 (-0.07), DXCM: 62.68 (+0.74), NVO: 43.76 (+0.61), MOM.VN: 0.210 (+0.005), LLY: 70.56 (+0.03)
Forget Pfizer! This Big Pharmaceutical Stock is Better
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 07, 1:04PM CST
Pfizer Inc . is one of the planet's biggest drugmakers and a staple in stock portfolios, but it faces a big problem that could suggest investors ought to own diabetes Goliath Novo Nordisk instead. Digging itself out of a hole Pfizer's...
NVO: 43.76 (+0.61), PFE: 34.64 (-0.23)
What MannKind Investors Can Learn From The Sanofi Conference Call
Psycho Analyst - at Seeking Alpha - Thu Feb 05, 1:37PM CST
NVO: 43.76 (+0.61), MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
Subcutaneous Drug Delivery Market & Pipeline Insight 2015
M2 - Thu Feb 05, 3:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/rjgnl5/subcutaneous_drug) has announced the addition of the "Subcutaneous Drug Delivery Market & Pipeline Insight" report to their offering. Subcutaneous sites along with intramuscular and intravenous sites are part of parenteral route of drug entry. Maximum pharmacological benefits of a drug could be achieved by deciding effective route of administration depending upon pharmacodynamic properties of the drug to be used. Subcutaneous route is commonly used for the administration of therapeutics into the body for better drug delivery of lipophilic, proteinecious, small molecule drugs. It is characterized by less vasculature, fat rich and less metabolic activity prevents the degradation of drugs resulting in long last effect and higher therapeutic effects. Subcutaneous sites are versatile routes of administration that can be used for long-term therapeutic benefits. Implants are also placed in this site due to less nerve ending so that pain or discomfort is not produced when such devices are placed at the site. Owing to enormous fat reserves, they are found to have good absorbability for lipid soluble drugs which allows the researchers to design drugs according to the nature of subcutaneous site. Some drugs can't be used via other routes due to difference in their biochemical nature could be administrated subcutaneously. This site is metabolically less active due to which administrated drugs have lesser chances of degradation, enzyme activity and metabolic breakdown as a result of which many drugs could be administrated subcutaneously. Subcutaneous Drug Delivery Market & Pipeline Insight Report Findings - Subcutaneous Drug Delivery Market Overview - Devices for Subcutaneous Drug Delivery - Subcutaneous Drug Delivery Market Future Prospects - Subcutaneous Drug Clinical Pipeline by Company, Indication & Phase - Global Subcutaneous Drug Clinical Pipeline: 741 Drugs - Global Marketed Subcutaneous Drugs: 228 Drugs - Marketed Subcutaneous Drug Clinical Insight Key Topics Covered: 1. Introduction to Subcutaneous Drug Delivery 2. Mechanism of Subcutaneous Drug Delivery 3. Subcutaneous Drug Delivery Market Overview 4. Subcutaneous Drug Delivery Market Dynamics 5. Devices for Subcutaneous Drug Delivery 6. Subcutaneous Drug Delivery Market Future Prospects 7. Subcutaneous Drug Clinical Pipeline by Company, Indication & Phase 8. Marketed Subcutaneous Drug Clinical Insight 9. Discontinued & Suspended Subcutaneous Drugs in Clinical Trials 10. Competitive Landscape Companies Mentioned - Boehringer Ingelheim - Eli Lily - Galaxo - HMD pharmaceuticals - Merck - Novartis - Novo Nordisk - Pfizer - Sanofi - Teva Pharmaceutical - Zogenix For more information visit http://www.researchandmarkets.com/research/rj...neous_drug
NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), LXRX: 0.89 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
With Flat Qsymia Sales, Vivus May Shift Focus To Stendra/Spedra
Spencer Osborne - at Seeking Alpha - Tue Feb 03, 1:44PM CST
NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 30 January 2015
GlobeNewswire - Mon Feb 02, 9:28AM CST
In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.
NVO: 43.76 (+0.61)
Novo Nordisk's Q4 Earnings Rise Y/Y, Provides 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:46AM CST
Novo Nordisk's fourth-quarter 2014 earnings increased 1.7% year over year to $0.42 per share.
MNK: 115.01 (+2.51), IPXL: 39.51 (+0.69), NVO: 43.76 (+0.61), ABBV: 58.05 (+1.00)
Baxter Announces Positive Data for BAX 855; Competition Rife - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 12:40PM CST
Baxter International Inc. (BAX) recently disclosed additional efficacy and safety data from its Phase III pivotal study evaluating BAX 855 which is used to treat patients with hemophilia A.
NVO: 43.76 (+0.61), BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)
Research and Markets: Global Insulin Delivery Devices Market 2014-2018: Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co Account for 90% of Global Share
Business Wire - Wed Feb 11, 11:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/jgc6fb/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering.
NVO: 43.76 (+0.61), LLY: 70.56 (+0.03)
Global Insulin Delivery Devices Market 2014-2018: Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co Account for 90% of Global Share
M2 - Wed Feb 11, 9:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/hjxrhm/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. This study thus leads to the proposition that innovation has huge scope in the field of insulin delivery and its analysts have elaborate information on some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co. These players together account for more than 90% of the global market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/hj...al_insulin
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), PODD: 32.00 (-0.07), NVO: 43.76 (+0.61), MDT: 75.26 (+0.33), LLY: 70.56 (+0.03)
Don't Worry About Orexigen's Obesity Drug EU Approval
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 10, 8:34AM CST
Someone in Europe isn't too happy that Orexigen 's obesity drug, Mysimba, got a positive recommendation from the Committee for Medicinal Products for Human Use, or CHMP. The drug, which goes by the name Contrave in the U.S., will be reviewed in a...
JNJ: 99.62 (+1.18), OREX: 5.55 (+0.10), ECYT: 5.26 (-0.02), NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
International GPCR Consortium Announces Addition of New Members Novo Nordisk and Merck & Co., Inc
PR Newswire - Tue Feb 10, 7:00AM CST
The GPCR Consortium, an international nonprofit collaboration that comprises leading academic research institutes in the United States and China and major pharmaceutical companies from around the world, today announced two new members. Novo Nordisk and Merck & Co., Inc, known as MSD outside the United States and Canada, have joined Amgen, Sanofi and Ono in the GPCR Consortium, bringing the current pharma membership to five. The research funded by the GPCR Consortium is currently conducted at the Bridge Institute at the University of Southern California, Shanghai Institute of Materia Medica, and the iHuman Institute at ShanghaiTech University.
NVO: 43.76 (+0.61), AMGN: 153.48 (+0.30)
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 6 February 2015
GlobeNewswire - Mon Feb 09, 8:05AM CST
In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.
NVO: 43.76 (+0.61)
Forget About Ebola Stocks and Invest in This Instead
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:59AM CST
There's no question that Ebola is a frightening disease that requires significant attention, but investors should be careful about how much of their portfolio they invest in companies pursuing Ebola therapies. After all, Ebola is an uncommon disease,...
OREX: 5.55 (+0.10), VRTX: 113.66 (+4.03), NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), QSII: 17.04 (+0.38), MDRX: 11.80 (+0.04), ARNA: 4.55 (+0.02)
Novo Nordisk A/S : Novo Nordisk A/S - Share repurchase programme
GlobeNewswire - Mon Feb 09, 7:36AM CST
On 30 January 2015, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2015.
NVO: 43.76 (+0.61)
Miraculins Moves Closer to Commercialization
ACCESSWIRE - Mon Feb 09, 7:01AM CST
WHITEFISH, MT / ACCESSWIRE / February 9, 2015 / Diabetes is the seventh leading cause of death in the United States with over a million new cases each year, according to the American Diabetes Association, costing the healthcare system $176 billion in direct costs and the economy $76 billion in lost productivity in 2012.
PODD: 32.00 (-0.07), DXCM: 62.68 (+0.74), NVO: 43.76 (+0.61), MOM.VN: 0.210 (+0.005), LLY: 70.56 (+0.03)
Forget Pfizer! This Big Pharmaceutical Stock is Better
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 07, 1:04PM CST
Pfizer Inc . is one of the planet's biggest drugmakers and a staple in stock portfolios, but it faces a big problem that could suggest investors ought to own diabetes Goliath Novo Nordisk instead. Digging itself out of a hole Pfizer's...
NVO: 43.76 (+0.61), PFE: 34.64 (-0.23)
What MannKind Investors Can Learn From The Sanofi Conference Call
Psycho Analyst - at Seeking Alpha - Thu Feb 05, 1:37PM CST
NVO: 43.76 (+0.61), MNKD: 7.00 (+0.02), SNY: 49.42 (+0.82)
Subcutaneous Drug Delivery Market & Pipeline Insight 2015
M2 - Thu Feb 05, 3:10AM CST
Research and Markets (http://www.researchandmarkets.com/research/rjgnl5/subcutaneous_drug) has announced the addition of the "Subcutaneous Drug Delivery Market & Pipeline Insight" report to their offering. Subcutaneous sites along with intramuscular and intravenous sites are part of parenteral route of drug entry. Maximum pharmacological benefits of a drug could be achieved by deciding effective route of administration depending upon pharmacodynamic properties of the drug to be used. Subcutaneous route is commonly used for the administration of therapeutics into the body for better drug delivery of lipophilic, proteinecious, small molecule drugs. It is characterized by less vasculature, fat rich and less metabolic activity prevents the degradation of drugs resulting in long last effect and higher therapeutic effects. Subcutaneous sites are versatile routes of administration that can be used for long-term therapeutic benefits. Implants are also placed in this site due to less nerve ending so that pain or discomfort is not produced when such devices are placed at the site. Owing to enormous fat reserves, they are found to have good absorbability for lipid soluble drugs which allows the researchers to design drugs according to the nature of subcutaneous site. Some drugs can't be used via other routes due to difference in their biochemical nature could be administrated subcutaneously. This site is metabolically less active due to which administrated drugs have lesser chances of degradation, enzyme activity and metabolic breakdown as a result of which many drugs could be administrated subcutaneously. Subcutaneous Drug Delivery Market & Pipeline Insight Report Findings - Subcutaneous Drug Delivery Market Overview - Devices for Subcutaneous Drug Delivery - Subcutaneous Drug Delivery Market Future Prospects - Subcutaneous Drug Clinical Pipeline by Company, Indication & Phase - Global Subcutaneous Drug Clinical Pipeline: 741 Drugs - Global Marketed Subcutaneous Drugs: 228 Drugs - Marketed Subcutaneous Drug Clinical Insight Key Topics Covered: 1. Introduction to Subcutaneous Drug Delivery 2. Mechanism of Subcutaneous Drug Delivery 3. Subcutaneous Drug Delivery Market Overview 4. Subcutaneous Drug Delivery Market Dynamics 5. Devices for Subcutaneous Drug Delivery 6. Subcutaneous Drug Delivery Market Future Prospects 7. Subcutaneous Drug Clinical Pipeline by Company, Indication & Phase 8. Marketed Subcutaneous Drug Clinical Insight 9. Discontinued & Suspended Subcutaneous Drugs in Clinical Trials 10. Competitive Landscape Companies Mentioned - Boehringer Ingelheim - Eli Lily - Galaxo - HMD pharmaceuticals - Merck - Novartis - Novo Nordisk - Pfizer - Sanofi - Teva Pharmaceutical - Zogenix For more information visit http://www.researchandmarkets.com/research/rj...neous_drug
NVO: 43.76 (+0.61), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), LXRX: 0.89 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
With Flat Qsymia Sales, Vivus May Shift Focus To Stendra/Spedra
Spencer Osborne - at Seeking Alpha - Tue Feb 03, 1:44PM CST
NVO: 43.76 (+0.61), VVUS: 2.68 (+0.13), ARNA: 4.55 (+0.02)
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 30 January 2015
GlobeNewswire - Mon Feb 02, 9:28AM CST
In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.
NVO: 43.76 (+0.61)
Novo Nordisk's Q4 Earnings Rise Y/Y, Provides 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 8:46AM CST
Novo Nordisk's fourth-quarter 2014 earnings increased 1.7% year over year to $0.42 per share.
MNK: 115.01 (+2.51), IPXL: 39.51 (+0.69), NVO: 43.76 (+0.61), ABBV: 58.05 (+1.00)
